{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:12Z","timestamp":1792427772732,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jaip.2024.09.021","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:37:55Z","timestamp":1727455075000},"page":"2917-2932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi"],"prefix":"10.1016","volume":"12","author":[{"given":"Kathleen M.","family":"Buchheit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Vandewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester B.E.","family":"Elzinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietze","family":"Reitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippe","family":"Geveart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.09.021_bib1","first-page":"281","article-title":"Concerning the nature of intolerance to aspirin","volume":"40","author":"Samter","year":"1967","journal-title":"J\u00a0Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1081-1206(10)62084-4","article-title":"The natural history and clinical characteristics of aspirin-exacerbated respiratory disease","volume":"89","author":"Berges-Gimeno","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib3","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib4","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaci.2005.08.035","article-title":"Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma","volume":"116","author":"Mascia","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2466-13-46","article-title":"Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German National Health Telephone Interview Survey (GEDA) 2010","volume":"13","author":"Steppuhn","year":"2013","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib6","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2500\/ajr.2006.20.2913","article-title":"Medical and surgical considerations in patients with Samter's triad","volume":"20","author":"McMains","year":"2006","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/000348941112000304","article-title":"Revision rates after endoscopic sinus surgery: a recurrence analysis","volume":"120","author":"Mendelsohn","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaip.2024.09.021_bib9","first-page":"925","article-title":"Associations between the quality of life and nasal polyp size in patients suffering from chronic rhinosinusitis without nasal polyps, with nasal polyps or aspirin-exacerbated respiratory disease","volume":"9","author":"Schneider","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"Swierczynska-Krepa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/alr.21826","article-title":"Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations","volume":"6","author":"Levy","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaci.2017.05.006","article-title":"Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study","volume":"141","author":"Waldram","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/alr.22428","article-title":"Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis","volume":"9","author":"Chu","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib18","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1016\/j.jaip.2020.06.063","article-title":"High discontinuation rates of peroral ASA treatment for CRSwNP: a real-world multicenter study of 171 N-ERD patients","volume":"8","author":"Laulajainen-Hongisto","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib19","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib20","first-page":"S22","article-title":"International Consensus Statement on Allergy and Rhinology: rhinosinusitis","volume":"6","author":"Orlandi","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib23","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jaip.2022.06.016","article-title":"The role of omalizumab in NSAID-exacerbated respiratory disease: a narrative review","volume":"10","author":"Taniguchi","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2024.09.021_bib25","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jaci.2021.06.019","article-title":"Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib27","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1164\/rccm.202003-0783ED","article-title":"Does IgE have a role in aspirin-exacerbated respiratory disease?","volume":"201","author":"Busse","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaci.2022.09.012","article-title":"Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: a hypothesis","volume":"151","author":"Picado","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib32","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib33","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. a randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaip.2016.12.013","article-title":"Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug\u2013exacerbated respiratory disease following treatment with omalizumab","volume":"5","author":"Phillips-Angles","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb7221","article-title":"Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation","volume":"6","author":"Dwyer","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib37","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/lary.27564","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2019","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2024.09.021_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2023.10.011","article-title":"Nasal polyp antibody-secreting cells display proliferation signature in aspirin-exacerbated respiratory disease","volume":"153","author":"Sohail","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib39","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.09.021_bib40","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/00034894231176334","article-title":"Effect of dupilumab on type 2 biomarkers in chronic rhinosinusitis with nasal polyps: SINUS-52 study results","volume":"132","author":"Bachert","year":"2023","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaip.2024.09.021_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib42","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/all.15222","article-title":"Dupilumab improves health related quality of life: results from the phase 3 SINUS studies","volume":"77","author":"Lee","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/alr.23249","article-title":"Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52","volume":"14","author":"Bachert","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib44","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2024.09.021_bib46","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib47","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/cea.14348","article-title":"Co-treatment of non-steroidal anti-inflammatory drug\u2013exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization","volume":"53","author":"Buchheit","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib48","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/all.13984","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"75","author":"Bachert","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib50","first-page":"10","article-title":"Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP","volume":"58","author":"Bachert","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1433","article-title":"Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps","volume":"12","author":"Gevaert","year":"2023","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib53","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2024.04.020","article-title":"IL-4R\u03b1 signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease","volume":"154","author":"Chen","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib54","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1111\/all.15877","article-title":"Inflammatory innate lymphoid cells predict response speed to dupilumab in chronic rhinosinusitis with nasal polyps","volume":"78","author":"Golebski","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib55","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jaci.2006.01.049","article-title":"Selective downregulation of prostaglandin E2\u2013related pathways by the Th2 cytokine IL-13","volume":"117","author":"Trudeau","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib56","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib57","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene\u2013driven IL-33\u2013mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2024.09.021_bib60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib61","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jaci.2021.12.759","article-title":"Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)","volume":"149","author":"Gevaert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib62","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/mol.115.101832","article-title":"Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy","volume":"89","author":"Sykes","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaip.2024.09.021_bib63","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/cea.14158","article-title":"Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: a randomized controlled clinical trial","volume":"52","author":"Price","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib64","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15434","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis","volume":"78","author":"Fokkens","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib65","first-page":"108","article-title":"Evaluating treatment response to mepolizumab in patients with severe CRSwNP","volume":"61","author":"Hopkins","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib66","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib67","first-page":"37","article-title":"Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and anti-IL-5 biologics: a real-life study","volume":"33","author":"Barroso","year":"2023","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib68","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/biomedicines11020485","article-title":"Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dom\u00ednguez-Sosa","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaip.2024.09.021_bib69","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2024.09.021_bib70","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib71","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib72","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/alr.23219","article-title":"Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up","volume":"14","author":"Desrosiers","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib76","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","author":"Jackson","year":"2024","journal-title":"N\u00a0Engl J Med."},{"key":"10.1016\/j.jaip.2024.09.021_bib77","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib78","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib79","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib80","first-page":"531","article-title":"The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP","volume":"61","author":"Lee","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib81","first-page":"202","article-title":"Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps","volume":"62","author":"Kemp","year":"2024","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib82","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib83","article-title":"Dupilumab in chronic rhinosinusitis with nasal polyps: real life data in a multicentric Sicilian experience","volume":"45","author":"Galletti","year":"2024","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.jaip.2024.09.021_bib84","first-page":"2684","article-title":"Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a \"real-life\" observational study in the first year of treatment","volume":"11","author":"De Corso","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jaip.2024.09.021_bib85","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib86","first-page":"403","article-title":"Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP","volume":"62","author":"Otten","year":"2024","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib87","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/JAA.S391896","article-title":"Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma irrespective of baseline asthma characteristics","volume":"16","author":"Busse","year":"2023","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib88","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib89","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib90","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01335-2022","article-title":"Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease","volume":"61","author":"Schneider","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.09.021_bib91","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jaip.2024.03.011","article-title":"Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease","volume":"12","author":"Brown","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib92","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib93","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.anai.2022.01.036","article-title":"Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Miss Ozuna","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib94","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/alr.23108","article-title":"Dupilumab-related adverse events among patients with chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Lee","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib95","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib96","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib97","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib98","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib99","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1945892420972326","article-title":"Effects of omalizumab treatment in patients with recalcitrant nasal polyposis and mild asthma: a multicenter retrospective study","volume":"35","author":"Armengot-Carceller","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaip.2021.09.050","article-title":"Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug\u2013exacerbated respiratory disease patients is independent of atopic sensitization","volume":"10","author":"Quint","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib101","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2021.12.030","article-title":"Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease\u2014how to choose","volume":"10","author":"Laidlaw","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib102","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5414\/ALX02296E","article-title":"Epithelial immune regulation of inflammatory airway diseases: chronic rhinosinusitis with nasal polyps (CRSwNP)","volume":"6","author":"Klimek","year":"2022","journal-title":"Allergol Select"},{"key":"10.1016\/j.jaip.2024.09.021_bib103","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/all.15986","article-title":"Tezepelumab in patients with allergic and eosinophilic asthma","volume":"79","author":"Caminati","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib104","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s12325-024-02889-8","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma across multiple clinically relevant subgroups in the NAVIGATOR study","volume":"41","author":"Carr","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2024.09.021_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.332","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma with aspirin exacerbated respiratory disease: results from the NAVIGATOR study","volume":"153","author":"Bernstein","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib106","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib107","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.09.021_bib108","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib109","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib110","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00405-024-08461-y","article-title":"Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP","volume":"281","author":"Rosso","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2024.09.021_bib111","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4193\/Rhin22.408","article-title":"Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD","volume":"61","author":"Brkic","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2024.09.021_bib112","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.anai.2022.04.004","article-title":"Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps","volume":"129","author":"Borish","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib113","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.jaip.2023.04.033","article-title":"Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: a randomized comparative trial","volume":"11","author":"Sanchez","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib114","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib115","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: a case series","volume":"9","author":"Martin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaip.2023.09.019","article-title":"Should biologics be used before aspirin desensitization in aspirin-exacerbated respiratory disease?","volume":"12","author":"Laidlaw","year":"2024","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib117","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/alr.23059","article-title":"A\u00a0comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Miglani","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib118","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/alr.22951","article-title":"Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"12","author":"Dharmarajan","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib119","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00405-023-08309-x","article-title":"Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report","volume":"281","author":"Orlando","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2024.09.021_bib120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.wjorl.2020.06.002","article-title":"Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: a review of preliminary data, efficacy, and cost","volume":"6","author":"Workman","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2024.09.021_bib121","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"131","author":"Scangas","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2024.09.021_bib122","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2021.11.020","article-title":"Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Patel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib123","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/alr.23246","article-title":"Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)","volume":"14","author":"Garvey","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib124","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.anai.2019.07.015","article-title":"Aspirin desensitization or biologics for AERD?","volume":"123","author":"Steinke","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","article-title":"An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"121","author":"Shaker","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.09.021_bib126","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1016\/j.jaip.2021.01.039","article-title":"Lower use of biologics for the treatment of asthma in publicly insured individuals","volume":"9","author":"Akenroye","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.09.021_bib127","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/alr.22976","article-title":"Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population","volume":"12","author":"Rathi","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2024.09.021_bib128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00106-024-01433-y","article-title":"Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization: results of a multicentric study","volume":"72","author":"Staufenberg","year":"2024","journal-title":"HNO"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824009474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824009474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T15:40:45Z","timestamp":1732117245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824009474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":128,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2213219824009474"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.09.021","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}